Abstract |
In a randomized single-blind study, 13 healthy adult volunteers were subcutaneously immunized with 2 or 3 single 50 or 400 micrograms doses of a Plasmodium falciparum recombinant vaccine candidate designated 5.1-[NANP]19. The vaccine caused transitory reactions at the injection site. Eight (62%) volunteers had a greater than or equal to 4-fold increase of antibody titer against sporozoites in immunofluorescence assay, all 13 seroconverted in IgG enzyme-linked immunosorbent assay against [NANP]50 antigen, and in 6 (46%) a lymphocyte proliferation index greater than or equal to 3 against 5.1 antigen was observed. Seven volunteers were challenged with mosquitoes infected with P. falciparum. All developed detectable parasitemia after 7 to 12 days and all received drug therapy within 24 hours. One volunteer with a cellular response to 5.1 had two negative in vitro parasite cultures before treatment, despite overt parasitemia. He was the only challenged volunteer who remained free of malaria symptoms.
|
Authors | D Stürchler, M Just, R Berger, R Reber-Liske, H Matile, H Etlinger, B Takacs, C Rudin, M Fernex |
Journal | Tropical and geographical medicine
(Trop Geogr Med)
Vol. 44
Issue 1-2
Pg. 9-14
(Jan 1992)
ISSN: 0041-3232 [Print] Netherlands |
PMID | 1496731
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antigens, Protozoan
- Protozoan Proteins
- Protozoan Vaccines
- QF116 antigen, Plasmodium falciparum
- Vaccines, Synthetic
- circumsporozoite protein, Protozoan
|
Topics |
- Adult
- Animals
- Antibody Formation
- Antigens, Protozoan
(immunology)
- Enzyme-Linked Immunosorbent Assay
- Female
- Fluorescent Antibody Technique
- Humans
- Injections, Subcutaneous
- Lymphocyte Activation
- Male
- Middle Aged
- Plasmodium falciparum
(immunology)
- Protozoan Proteins
- Protozoan Vaccines
(administration & dosage, adverse effects, therapeutic use)
- Vaccines, Synthetic
(administration & dosage, adverse effects, therapeutic use)
|